Ciobanu, A.C., Caseiro, D.M., Niu, R. et al. Negative allosteric modulation of mGlu7 disrupts fear memory reconsolidation and glutamatergic signaling in rat and human brain tissue. Mol Psychiatry ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...

Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...

Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...

Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...

Researchers from Alzecure Pharma AB presented preclinical data for ACD-137, a negative allosteric modulator (NAM) of tropomyosin receptor kinase A (TrkA), being developed for the treatment of pain.

Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...